Industry News
Pharmaceutical Industry News
Moderna will pay $950 million…
Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roivant subsidiary Genevant and infectious disease biotech Arbutus back in 2022.
Patient Advocate Foundation and…
Patient Advocate Foundation and PAN Foundation announce merger, creating a single destination for patients facing access and affordability challenges.
NoA Health has appointed Louisa…
NoA Health has appointed Louisa Lee as CEO, putting the former Novo Nordisk and Pfizer employee at the head of the creative agency’s push to take its business global.
Sanofi is betting $1.53 billion on…
Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s hematology and immunology pipeline.
Trump, Iran and a Host of Questions
Questions about the future of the attack on Iran, and other reader perspectives. Also: Drug ads as a resource for patients.
In the letters sent to 30…
In the letters sent to 30 different telehealth companies that market compounded versions of GLP-1 drugs, the agency threatened "legal action without further notice."
Pfizer CEO Albert Bourla, Ph.D.,…
Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of the Center for Biologics Evaluation and Research, which regulates vaccines in
Amid an influx of U.S….
Amid an influx of U.S. investments, geopolitical uncertainties support the need for manufacturing projects in other regions, IDA Ireland's Rory Mullen told Fierce.
Dr. McDreamy has signed onto yet…
Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with Amgen since 2007 and joined forces with Pfizer in 2024, is now collaborating with cancer test
The FDA is providing more insight…
The FDA is providing more insight into the rejections it recently handed two pharma giants, publishing the complete response letters (CRLs) sent to AstraZeneca and GSK that highlight shortfalls in the data included in their
Novo will invest 432 million euros…
Novo will invest 432 million euros ($501 million) to add a new tableting plant at its facility in Athlone, Ireland, the company said in a March 2 press release. The expansion will equip the Athlone
Esperion has acquired Corstasis…
Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago. Esperion paid $75 million upfront and earmarked $180 million for potential milestones while agreeing to pay
As Kennedy Turns From Vaccines, MAHA Allies See a ‘Betrayal’
As the midterm elections approach, the health secretary is focusing on “real food.” Anger is rising among some of his supporters.
States Move to Limit Access to H.I.V. Treatment
Citing rising costs and shortfalls in federal support, about 20 states are toughening eligibility requirements for patients in drug assistance programs.
As it ramps up its rollout of the…
As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.
Since GLP-1 blockbusters…
Since GLP-1 blockbusters semaglutide and tirzepatide broke into the mainstream for their ability to treat diabetes and provoke weight loss, evidence has been piling up that the molecules can reduce the risk of heart problems
As the effects of the United…
As the effects of the United States and Israel’s weekend attack on Iran begin to ripple through the Middle East, multiple drugmakers operating in the region are taking stock of their local workforces’ safety and
The newest additions to the CDC’s…
The newest additions to the CDC's vaccine advisory committee are Florida internal medicine and pediatrics specialist Sean G. Downing, M.D., and pediatrician Angelina Farella, M.D.
With some 12 years as CEO under…
With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based vaccine maker. The planned move comes shortly after another high-profile exit at the company, with
Ascendis Pharma is spiraling…
Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based biopharma has scored an FDA approval for a rare disease medicine that was developed with